Aptinyx to Acquire Relmada Therapeutics
Ticker: RLMD · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, deal-agreement
TL;DR
Aptinyx is buying Relmada for $1.65/share cash, deal expected Q3 2025.
AI Summary
Relmada Therapeutics, Inc. announced on June 17, 2025, that it has entered into a definitive agreement to be acquired by Aptinyx Inc. for approximately $1.65 per share in cash. This transaction is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition could lead to significant changes for both companies' pipelines and market presence, potentially impacting investors and the competitive landscape in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and there's always a risk of the deal falling through or regulatory hurdles.
Key Numbers
- $1.65 — Acquisition Price per Share (Cash consideration for Relmada shareholders)
- Q3 2025 — Expected Closing (Anticipated timeframe for deal completion)
Key Players & Entities
- Relmada Therapeutics, Inc. (company) — Registrant
- Aptinyx Inc. (company) — Acquiring company
- $1.65 per share (dollar_amount) — Acquisition price
- June 17, 2025 (date) — Date of agreement
- Third quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition?
The filing does not explicitly state the total value, but it is based on an acquisition price of approximately $1.65 per share in cash.
Who is acquiring Relmada Therapeutics?
Aptinyx Inc. is acquiring Relmada Therapeutics.
When is the acquisition expected to be completed?
The transaction is expected to close in the third quarter of 2025.
What is the form of consideration for the acquisition?
The consideration is approximately $1.65 per share in cash.
Are there any specific conditions for the closing of the acquisition?
Yes, the transaction is subject to customary closing conditions.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding RELMADA THERAPEUTICS, INC. (RLMD).